Nab-paclitaxel, cisplatin, and capecitabine versus cisplatin and gemcitabine as first line chemotherapy in patients with recurrent or metastatic nasopharyngeal …
1. 请及时下载文件确认是否正确, 系统将在 2026-08-26 16:38:50 删除文件
2. 如若文件有误请驳回应助文件, 求助状态即回到求助中
3. 如若文件正确请及时点击确认, 若超过时后系统自动默认为已完结
注: 所有应助的资源仅供学习交流使用, 不得违反相关法律法规
DOI:
文献链接:
其他信息:
GY Liu, YF Ye, YF Jiang, GJ Chen, WX Xia, YS Huang…
Bmj, 2024
bmj.com
Objective To compare the effectiveness and safety of nab-paclitaxel, cisplatin, and capecitabine (nab-TPC) with gemcitabine and cisplatin as an alternative first line treatment option for recurrent or metastatic nasopharyngeal carcinoma. Design Phase 3, open label, multicentre, randomised trial. Setting Four hospitals located in China between September 2019 and August 2022. Participants Adults (≥ 18 years) with recurrent or metastatic nasopharyngeal carcinoma. Interventions Patients were randomised in a 1: 1 ratio to …
